ArticleOncogene2004
Identification of an epigenetically silenced gene, RFX1, in human glioma cells using restriction landmark genomic scanning.
Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Hypoglycemic Agents Increase Regulatory Factor X1 to Inhibit Cancer Cell Behaviour in Human Glioblastoma Cells.Journal of cellular and molecular medicine · 2024Article
- RFX1: a promising therapeutic arsenal against cancer.Cancer cell international · 2021Review
- RFX1 downregulation contributes to TLR4 overexpression in CD14Clinical epigenetics · 2019Article
- Regulatory Factor X1 Downregulation Contributes to Monocyte Chemoattractant Protein-1 Overexpression in CD14+ MonocytesFrontiers in genetics · 2019Article
- IL-6/STAT3 pathway induced deficiency of RFX1 contributes to Th17-dependent autoimmune diseases via epigenetic regulation.Nature communications · 2018Article
- Primary cilium and glioblastoma.Therapeutic advances in medical oncology · 2018Review
- Expression of regulatory factor X1 can predict the prognosis of breast cancer.Oncology letters · 2017Article
- Identifying survival-associated modules from the dysregulated triplet network in glioblastoma multiforme.Journal of cancer research and clinical oncology · 2017Article
- Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation.BMC cancer · 2015Article
- Regulatory factor X1 is a new tumor suppressive transcription factor that acts via direct downregulation of CD44 in glioblastoma.Neuro-oncology · 2014Article
- Characterization of the properties of seven promoters in the motor cortex of rats and monkeys after lentiviral vector-mediated gene transfer.Human gene therapy methods · 2013Article
- Regulatory factor X1-induced down-regulation of transforming growth factor β2 transcription in human neuroblastoma cells.The Journal of biological chemistry · 2012Article
- Study of FoxA pioneer factor at silent genes reveals Rfx-repressed enhancer at Cdx2 and a potential indicator of esophageal adenocarcinoma development.PLoS genetics · 2011Article
- A GAG trinucleotide-repeat polymorphism in the gene for glutathione biosynthetic enzyme, GCLC, affects gene expression through translation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2011Article
- Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells.Molecular cancer · 2011Article
- DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.Neuro-oncology · 2011Article
- Palate morphogenesis: current understanding and future directions.Birth defects research. Part C, Embryo today : reviews · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To identify the CpG islands differentially methylated in human glioma, we performed restriction landmark genomic scanning with a CpG methylation-sensitive enzyme. We found 12 spots, the intensity of which was entirely lost or decreased in both the human glioma tissues examined as compared with that in matched normal lymphocytes, indicating aberrant methylation of these CpG islands in gliomas. The expression of RFX1, one of the genes associated with the methylated CpG islands, was frequently decreased in human glioma cell lines and tissues. We also demonstrated that the isolated CpG island located in the seventh intron of the RFX1 gene had enhancer activity and was hypermethylated in all of the glioma tissues and cell lines analysed, but not in normal brains or lymphocytes. Treatment of glioma cells with a demethylating agent, 5-azacytidine, resulted in the expression of RFX1, indicating that the silencing of the RFX1 gene may be attributable to its methylation. RFX1 has been implicated in transcriptional downregulation of the proto-oncogene c-myc. By expression of the RFX1 gene, the cellular proliferative activity of glioma cells was suppressed. Taken together, these results suggest that the RFX1 gene may be epigenetically silenced in human gliomas and involved in glioma tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.